[A Case with Multiple Comorbidities of Obsessive-Compulsive and Related Disorders].

Obsessive-compulsive and related disorders (OCRDs) have been introduced in a revision to DSM-5 as a novel category that is distinct from other anxiety disorders in DSM-IV. OCRDs consist of 5 primary disorders: obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), hoarding disorder (HD), skin picking disorder (SPD), and hair pulling disorder (HPD), which share core clinical features such as preoccupation or recurrent thoughts and/or repetitive behaviors. Repetitive behaviors in BDD and HD can be differentially characterized by the presence of cognitive components associated with preceding anxiety from those in SPD or HPD, which are only observed as motoric components that regulate emotions or alleviate tension. Thus, the validity of the OCRD category and specific interrelationships between each OCRD remain uncertain. In the present study, therefore, we presented a case of multiple comorbidities of OCRDs in order to discuss the nature of the OCRD category. Our patient was a 20-year-old female university student. At the age of 11 years old, she started picking at acne on her face. The psychopathological, and treatment features observed in this case indicated possible interrelationships among OCRDs, especially between cognitive and motoric OCRDs, which supported the clinical utility and continuous nature of this category.

The impacts of elevated autism spectrum disorder traits on clinical and psychosocial features and long-term treatment outcome in adult patients with obsessive-compulsive disorder.

BACKGROUND: While a close relation between obsessive-compulsive disorder (OCD) and autism spectrum disorder (ASD) has been pointed out, there are few studies that have investigated whether highly elevated ASD traits may have significant impacts on clinical and psychosocial features as well as long-term treatment outcome in adult OCD patients. METHODS: We assessed ASD traits using the Autism Spectrum Quotient (AQ) in 81 Japanese patients with OCD. The relation between degree of ASD traits and clinical and psychosocial variables and the 48-week treatment outcomes was analyzed in the subjects. RESULTS: A substantial proportion of the subjects showed higher ASD traits (35%) with more severe depressive or pervasive anxiety status, and social impairments and lower QOL compared to other OCD individuals. However, elevated ASD traits may exert rather smaller impact on the OCD phenomenology along with on the long-term treatment outcome than expected. CONCLUSIONS: Elevated ASD traits may further emphasize the general psychopathological and socio-dysfunctional features rather than clinical aspects associated with OCD. Co-existing depressive or anxious symptom severity may further exacerbate the core-deficits related to ASD pathology. Thus the assessment of ASD traits should be important for understanding the clinical and psychosocial features and treatment responses in OCD patients.

A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.

OBJECTIVE: For the obsessive compulsive disorder (OCD) patients refractory to selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, such as risperidone, or olanzapine have been found effective in the augmentation of SSRIs. However these atypical antipsychotics may cause a number of safety concerns associated with body weight or metabolic changes. We sought to investigate the efficacy and safety of a novel atypical neuroleptic aripiprazole as an augmenting agent for the treatment-resistant OCD. METHODS: Eleven patients who had previously been assessed as poorer responders (<10% reduction of Y-BOCS) to both adequate SSRI monotherapy such as fluvoxamine or paroxetine and the subsequent atypical antipsychotic augmentation of SSRIs were included in this study. The addition of aripiprazole to ongoing SSRIs was continued for at least 12 weeks in the subjects except for one who dropped out during the period. RESULTS: The mean maximum daily dosage of aripiprazole in the completers was 10.9 ± 3.4 mg/day. Seven of 10 completers exhibited significant reduction of Y-BOCS (>35%) accompanying a few adverse events. CONCLUSIONS: This preliminary study supports the notion that adding aripiprazole to SSRIs could be a valid and effective strategy for treatment-resistant OCD patients. Thus it points towards the need of further controlled and longitudinal studies.